Skip to main content

Table 1 Demographics and clinicopathological characteristics of EEC/AEH patients after achieving CR and attempting to conceive

From: Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia

  Total Non-pregnant Pregnant P value
Patients (n) 68 32 36 -
Age of initial treatment (years) 30.4 ± 3.9 31.0 ± 3.7 29.9 ± 4.1 0.272 a
Age of pregnancy permission (years) 31.9 ± 4.2 32.6 ± 3.8 31.2 ± 4.5 0.190 a
BMI c of initial treatment (kg/m2) 25.9 ± 4.2 26.9 ± 4.2 25.0 ± 3.9 0.051 a
BMI of pregnancy permission (kg/m2) 25.9 ± 3.8 27.2 ± 3.7 24.8 ± 3.6 0.007
Irregular menstrual cycle (%) 35 (51.5) 18 (56.2) 17 (47.2) 0.457 b
Infertility (%) 27 (39.7) 14 (43.8) 13 (36.1) 0.520b
Nulliparity (%) 62 (91.2) 30 (93.8) 32 (88.9) 0.481 b
Diabetes mellitus type 2 (%) 11 (16.2) 3 (9.4) 8 (22.2) 0.151 b
Insulin resistance (%) 21 (30.9) 10 (31.3) 11 (30.6) 0.950 b
High blood pressure (%) 6 (8.8) 2 (6.2) 4 (11.1) 0.481 b
Thyroid diseases (%) 9 (13.2) 4 (12.5) 5 (13.9) 0.866 b
Myometrium invasion in MRI (%) 16 (33.3) 8 (34.8) 8 (32.0) 0.581 b
PCO on ultrasonography (%) 37 (54.4) 20 (62.5) 17 (47.2) 0.207 b
PCOSd 27 (39.7) 13 (40.6) 14 (38.9) 0.884b
CA125 (U/mL) 22.4 ± 22.6 22.7 ± 16.2 22.2 ± 27.2 0.926 a
Histological type     0.214 b
 AEH 39 16 23  
 EEC G1 21 10 11  
 EEC G2 8 6 2  
Treatment protocol (%)     0.831 b
 MPA 250 mg, once daily 45 (67.2) 21 (65.6) 24 (68.6)  
 MPA 500 mg, once daily 8 (11.9) 5 (15.6) 3 (8.6)  
 MA 160-320 mg, once daily 9 (13.4) 4 (12.5) 5 (14.3)  
 GnRH-a 5 (7.5) 2 (6.2) 3 (8.6)  
Adjuvant metformin (%) 25 (36.8) 15 (46.9) 10 (27.8) 0.103 b
Maintenance therapy (%)     0.223 b
 None 11 (16.2) 6 (18.8) 5 (13.9)  
 Progestin 45 (66.2) 18 (56.2) 27 (75.0)  
 LNG-IUD 12 (17.6) 8 (25.0) 4 (11.1)  
Conception method (%)     0.246 b
 Natural 19 (27.9) 12 (37.5) 7 (19.4)  
 Ovulation induction ± IUI 9 (13.2) 4 (12.5) 5 (13.9)  
 IVF-ET 40 (58.8) 16 (50.0) 24 (66.7)  
  1. AEH atypical endometrial hyperplasia, BMI body mass index, CA cancer antigen, EEC early stage endometrial cancer, GnRH-a gonadotropin-releasing hormone agonist, IUI intrauterine insemination, IVF-ET in vitro fertilization and embryo transfer, LNG-IUD levonorgestrel intrauterine system, MA megestrol acetate, MPA medroxyprogesterone acetate, PCO polycystic ovary
  2. aPregnancy versus Non-pregnancy (Student’s t test)
  3. bPregnancy versus Non-pregnancy (Chi-squared test)
  4. cBMI, kg/m2 (Chinese Society for the Study of Obesity: normal BMI 18.5–23.9; overweight 24–28; obesity > 28)
  5. dDiagnostic criteria: the Rotterdam criteria 2003